Board Members

Professor David Blackbourn

Founder and non-exec board member

Is the Director of the Institute of Medical Sciences (IMS) at University of Aberdeen. The IMS is a community of clinical and bioscience researchers located on Aberdeen’s Foresterhill Health Campus, working in diverse biomedical research areas including arthritis and musculoskeletal medicine; developmental and cancer biology; immunity, infection and inflammation; metabolic and cardiovascular health; and translational neuroscience. 

Philippe Lenoble

Chairman and non-exec board member

Is an investment banker specialising in infrastructure finance and investment with Citibank (5 years), Goldman Sachs (16 years), CDPQ (a large Canadian pension fund) and, currently, AustralianSuper (the largest Australian pension fund). In a personal capacity, Philippe is a keen growth investor in the technology sector with 5 IPOs, small and large, in his portfolio.  Philippe is a Belgian citizen with a degree in engineering and management from the Universite Catholique de Louvain (Belgium), and MBA from the University of Georgetown and is a CFA charterholder.

Dr Alan Watt

Non-executive Board Member

Is a Biotech entrepreneur with substantial experience in drug discovery & development and therapeutic area expertise in neuroscience, immuno-inflammation, metabolic disease, and oncology. Alan is currently the Chief Scientific Officer at NodThera Therapeutics Ltd.. Before joining NodThera Alan held positions at Bicycle Therapeutics (CSO), Trident Pharmaceuticals Inc. (COO), Cellzome Ltd. (VP Therapeutics), senior management positions at GSK and senior scientist roles at the Merck Sharp and Dohme Neuroscience Research Centre.

Clare Terlouw

Non-executive Board Member

Is Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life science sector. She is the head of the investment team and a member of the Early Ventures Investment Committee. Clare was previously Head of Corporate Development at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust. Clare has 15 years of biotech and healthcare financing experience as an investment banker in the City of London, with significant expertise in growth funding for innovative life sciences companies in private and public markets.

Andrea Mica

Non-executive Board Member

Is a director at Oxford Technology Management (OTM) where he specialises in making and managing investments in start-up and early stage technology-based businesses. Andrea graduated from the Delft University of Technology with an MSc in Industrial Design Engineering and completed additional graduate study in Innovation and Creativity at the State University College of New York at Buffalo. He has a 25-year background identifying, promoting and investing in new technologies including 15 years in life science.